Alzheimer - International Biopharmaceutical Industry

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Subsection - Oncology

Essential DMPK Strategies for IND Success

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

news

Hint of benefit in Alzheimer’s drug study fuel stock surge for Swiss biotech

A small clinical trial of a once-failed Alzheimer's drug offered tantalizing but inconclusive hints of benefit, propelling shares in its biotech maker higher by more ...

3 September 2021 news Alzheimer | Biogen

Continue Reading →

news

Lilly, preparing Alzheimer’s drug plans, forms new neuroscience unit in company restructure

After numerous setbacks in Alzheimer's disease, Lilly has high hopes for a breakthrough with donanemab. When the FDA controversially approved Biogen's Aduhelm in June...

20 August 2021 news Aduhelm | Alzheimer

Continue Reading →

news

HHS watchdog to review FDA accelerated approval process after Aduhelm controversy

The U.S. health department's inspector general will review how the Food and Drug Administration grants accelerated approvals of new drugs, announcing a broad investig...